| name | PTH Analogs (e.g., Teriparatide, Abaloparatide) |
| classification | Bone-forming agents, specifically used in the treatment of osteoporosis |
| pharmacokinetics | | absorption | Subcutaneous injection. Absorption varies by formulation and route. | | distribution | Distributed throughout the body, affecting bone metabolism. | | metabolism | Metabolized primarily in the liver and kidneys. | | excretion | Excreted primarily in the urine. |
|
| suggested dosage | | note | Dosage and specific regimens are crucial and should be determined by a healthcare provider based on individual patient needs and conditions. The following is a general guideline and does not constitute medical advice. | | teriperatide | 20 mcg subcutaneously daily. | | abaloparatide | 20 mg subcutaneously daily. | | note2 | This information is for general knowledge and informational purposes only and does not constitute medical advice. Consult with a healthcare provider for specific dosage and treatment recommendations. Always follow your prescribed dosage instructions closely. |
|
| indications | | 1 | Treatment of osteoporosis in postmenopausal women at high risk of fracture. | | 2 | Treatment of osteoporosis in men at high risk of fracture. | | 3 | Glucocorticoid-induced osteoporosis (in some cases, under specific circumstances). |
|
| safety in pregnancy | Not recommended for use during pregnancy unless the potential benefit outweighs the potential risk. More research is needed in this area. |
| safety in breastfeeding | Not recommended for use during breastfeeding. |
| side effects | | 1 | Headache | | 2 | Nausea | | 3 | Leg cramps | | 4 | Dizziness | | 5 | Transient elevation of serum calcium | | 6 | Transient hypercalciuria | | 7 | Back pain | | 8 | Injection site reactions (e.g., redness, pain, swelling) | | 9 | Rare but serious side effects: bone pain, hypercalcemia |
|
| alternatives | |
| contraindications | | 1 | Hypercalcemia | | 2 | Renal insufficiency or impairment | | 3 | Hypersensitivity to PTH analogs | | 4 | History of bone malignancies | | 5 | Pregnancy or breastfeeding |
|
| interactions | | 1 | Thiazide diuretics (can increase calcium levels) | | 2 | Certain medications for hypothyroidism (can affect calcium metabolism) | | 3 | Oral calcium supplements (potentially increase calcium levels) | | 4 | Excessive intake of vitamin D (potentially increase calcium levels) |
|
| warnings and precautions | | 1 | Regular monitoring of calcium levels and renal function is important. | | 2 | Monitor for hypercalcemia (high blood calcium). | | 3 | Patients with renal impairment should be monitored carefully. Dosage adjustment might be necessary. | | 4 | Patients should be cautioned about the risk of bone pain or other musculoskeletal pain | | 5 | Discontinue therapy if any worsening of the condition is noted. | | 6 | Proper hydration is necessary |
|
| additional informations | PTH analogs stimulate bone formation, thus are useful in conditions where bone resorption is accelerated or bone mass needs to be increased. It is important to discuss the potential benefits and risks associated with these medications with a healthcare professional before starting therapy. |
| patient specific considerations | | age | 25 years: This medication may be a treatment option for prevention/treatment of future bone loss if other contributing factors are in place. | | weight | 70 kg: Weight is not a primary factor affecting dosage of these drugs. However, weight is one piece of information for a complete picture when assessing a patient for osteoporosis. | | general | A thorough evaluation by a medical professional is critical to assess the specific needs of this patient. Lifestyle factors like exercise and nutrition also play a role in bone health. |
|
